- Home
- MIN vs OTLK Comparison
MIN vs OTLK Comparison
Compare MIN & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MIN | OTLK |
|---|---|---|
| Founded | 1988 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.4M | 249.6M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | MIN | OTLK |
|---|---|---|
| Price | $14.11 | $0.51 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.03 |
| AVG Volume (30 Days) | 167.2K | ★ 3.8M |
| Earning Date | 01-01-0001 | 08-14-2026 |
| Dividend Yield | ★ 7.31% | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ 0.08 | N/A |
| Revenue | N/A | ★ $8,146,123.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6,355.64 |
| P/E Ratio | $177.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.27 | $0.16 |
| 52 Week High | $14.22 | $2.54 |
Technical Indicators
Market Signals| Indicator | MIN | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 97.99 | 31.51 |
| Support Level | $2.41 | $0.39 |
| Resistance Level | N/A | $0.53 |
| Average True Range (ATR) | 0.15 | 0.05 |
| MACD | 0.94 | -0.00 |
| Stochastic Oscillator | 99.29 | 29.32 |
Price Performance
Historical ComparisonAbout MIN MFS Intermediate Income Trust
Aberdeen Intermediate Income Fund is a diversified, closed-end fixed-income management investment company. The fund's investment objective is to seek high current income, but may also consider capital appreciation.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.